indazoles has been researched along with B-Cell Chronic Lymphocytic Leukemia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Bhargava, P; Danilov, AV; Dyer, MJS; Fegan, CD; Herbaux, C; Hillmen, P; Huang, X; Humeniuk, R; Jürgensmeier, JM; Karlin, L; Kio, EA; Mitra, SS; Rule, SA; Walter, HS; Yi, PC; Zhou, Z | 1 |
| Best, S; Danilov, AV; Goodyear, S; Hashiguchi, T; Kittai, AS; Lam, V; Okada, C; Park, B; Persky, DO; Spurgeon, SE; Thurlow, B | 1 |
| Alinari, L; Baiocchi, RA; Byrd, JC; Chen, TL; Harrington, B; Hertlein, E; Lehman, AM; Orlemans, E; Prouty, A; Sampath, D; Sloan, S; Truxall, J; Wasmuth, R; Woyach, JA | 1 |
| Stretton, O | 1 |
| Best, S; Danilov, AV; Kittai, A; Lam, V; Liu, T; Orand, K; Spurgeon, SE | 1 |
| Assouline, S; Awan, FT; Hill, B; Patel-Donnelly, D; Rao, AV; Sharman, JP; Thirman, MJ; Ye, W | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Burke, RT; Clarke, AS; Currie, KS; Dipaolo, JA; Druker, BJ; Lannutti, BJ; Loriaux, MM; Maciejewski, P; Meadows, S; Mitchell, SA; Spurgeon, SE | 1 |
| Abella, S; Boxer, M; Hawkins, M; Hu, J; Klein, L; Kolibaba, K; Sharman, J; Wu, M; Yasenchak, C | 1 |
| Abella-Dominicis, E; Barr, PM; Cheson, BD; Di Paolo, J; Dreiling, LK; Friedberg, JW; Greenwald, DR; Hawkins, MJ; He, J; Hu, J; Joshi, A; Lee, H; Liem, AK; Mclntyre, RE; O'Brien, SM; Reddy, A; Saylors, GB; Spurgeon, SE | 1 |
| Almejún, MB; Bezares, RF; Borge, M; Cabrejo, M; Colado, A; Dos Santos, P; Elías, EE; Fernández Grecco, H; Gamberale, R; Giordano, M; Podaza, E; Risnik, D; Slavutsky, I; Stanganelli, C | 1 |
| Carter, A; Cawley, JC; Glenn, MA; Hawkins, SF; Johnson, GG; Lin, K; Pettitt, AR; Zhuang, J | 1 |
| Coll-Mulet, L; Cosialls, AM; de Frias, M; de la Banda, E; Gil, J; González-Gironès, DM; Iglesias-Serret, D; Pons, G; Santidrián, AF | 1 |
| Datta, J; Jacob, ST; Kutay, H; Motiwala, T; Roy, S | 1 |
| Erdfelder, F; Filipovich, A; Gandhirajan, RK; Gehrke, I; Hallek, M; Hertweck, M; Kreuzer, KA; Paesler, J; Poll-Wolbeck, SJ; Uhrmacher, S | 1 |
| Cohen, JD; Lagoni, R; Longo, WL; Neville, AJ; O'Keefe, S; Riggs, C; Robins, HI; Schmitt, CL; Steeves, RA | 1 |
6 trial(s) available for indazoles and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Pyrazines; Pyrimidines; Quinazolinones; Salvage Therapy; Tissue Distribution | 2020 |
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Pyrazines; Receptors, Antigen, B-Cell; Syk Kinase | 2022 |
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptors, Antigen, B-Cell; Recurrence; Retreatment; Treatment Outcome | 2019 |
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Syk Kinase | 2015 |
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Cytokines; Early Termination of Clinical Trials; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Pneumonia; Protein Kinase Inhibitors; Purines; Pyrazines; Quinazolinones; Salvage Therapy; Syk Kinase | 2016 |
Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; In Vitro Techniques; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Mice; Mice, Inbred AKR; Middle Aged; Pilot Projects; Pyrazoles; Whole-Body Irradiation | 1990 |
10 other study(ies) available for indazoles and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines | 2021 |
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Topics: Adenine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; HSP90 Heat-Shock Proteins; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors | 2021 |
EHA 2021 Virtual Congress.
Topics: Activin Receptors, Type II; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; beta-Thalassemia; Graft vs Host Disease; Hematologic Diseases; Humans; Immunoglobulin Fc Fragments; Indazoles; Interleukin-1 Receptor-Associated Kinases; Internet; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Fusion Proteins; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic | 2021 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazines; Quinazolinones; Signal Transduction; Syk Kinase | 2014 |
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Cell Proliferation; Cells, Cultured; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Macrophages; Male; Middle Aged; Oxazines; Phagocytosis; Phosphorylation; Pyrazines; Pyridines; Receptors, Antigen, T-Cell; Rituximab; Syk Kinase; T-Lymphocytes; ZAP-70 Protein-Tyrosine Kinase | 2017 |
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Clone Cells; Enzyme Activation; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-akt; Signal Transduction | 2010 |
Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Benzylamines; Blotting, Western; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Tumor Suppressor Protein p53 | 2009 |
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Topics: B-Lymphocytes; Base Sequence; Blotting, Western; Catalytic Domain; Cell Line, Tumor; DNA Primers; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Pyrimidines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Substrate Specificity; Sulfonamides; ZAP-70 Protein-Tyrosine Kinase | 2010 |
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |